FDA Brief

Warning letters Drugs

FDA warning letter to

Randy J. Epstein, M.D./Chicago Cornea Consultants, Ltd.

High riskIssued Jun 14, 2023Posted Jun 20, 2023Center for Drug Evaluation and Research | CDER

FDA warns Dr. Epstein/Chicago Cornea Consultants over trial without IND and inadequate drug records.

What happened

FDA inspected the clinical site from September 19 to October 26, 2022, as part of its Bioresearch Monitoring Program. It found that Dr. Epstein, as sponsor-investigator, started and ran Protocol PXL-330, a study of riboflavin solutions with UVA light, in 32 subjects without submitting or having an IND in effect. It also found inadequate records of receipt, shipment, and other disposition of the investigational drugs.

What FDA found

  1. Dr. Epstein started and ran a clinical trial of investigational drugs in 32 subjects without submitting an IND or having one in effect.

    21 CFR 312.20(a), 312.20(b), and 312.40(a)
  2. Dr. Epstein did not keep adequate records showing receipt, shipment, or other disposition of the investigational riboflavin solutions.

    21 CFR 312.57(a)

What FDA wants

FDA asks Dr. Epstein to notify the office in writing within 15 business days of receipt of the letter about actions taken to prevent similar violations. It says failure to adequately address the matter may lead to regulatory action.

Who should pay attention

  • sponsor-investigators running investigator-initiated trials
  • clinical research sites and IRBs
  • companies relying on investigator-run trial data

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Center For Immunology Science, LLC

    FDA cites Center for Immunology Science for a clinical trial of heat-killed Mycobacterium smegmatis without an Investigational New Drug application.

    High risk
  2. Prodrome Sciences USA, LLC

    Prodrome Sciences studied its supplement ProdromeNeuro Oil as a dementia drug in 29 people without first filing an IND, FDA says.

    High risk
  3. Pamela K. Den Besten, DDS, MS

    FDA warned sponsor-investigator Pamela K. Den Besten for running a pediatric dental gel study without an IND, enrolling 43 subjects.

    High risk
  4. MG Infusions

    FDA warned MG Infusions it sells unlicensed fecal transplant products online without required approval.

    High risk